Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

1. Kohsaka, S.
2. Lam, C.S.P.
3. Kim, D.J.
4. Cavender, M.A.
5. Norhammar, A.
6. Jørgensen, M.E.
7. Birkeland, K.I.
8. Holl, R.W.
9. Franch-Nadal, J.
10. Tangri, N.
11. Shaw, J.E.
12. Ilomäki, J.
13. Karasik, A.
14. Goh, S.-Y.
15. Chiang, C.-E.
16. Thuresson, M.
17. Chen, H.
18. Wittbrodt, E.
19. Bodegård, J.
20. Surmont, F.
21. Fenici, P.
22. Kosiborod, M.
23. Wilding, J.P.
24. Khunti, K.
25. Birkeland, K.
26. Jørgensen, M.E.
27. Lam, C.S.
28. Gulseth, H.L.
29. Carstensen, B.
30. Bollow, E.
31. García Rodríguez, L.A.
32. Shaw, J.
33. Arnold, S.
34. Blak, B.T.
35. Saathoff, M.
36. Noguchi, Y.
37. Tan, D.
38. Williams, M.
39. Lee, H.W.
40. Greenbloom, M.
41. Kaidanovich-Beilin, O.
42. Yeo, K.K.
43. Bee, Y.M.
44. Khoo, J.
45. Koong, A.
46. Lau, Y.H.
47. Gao, F.
48. Tan, W.B.
49. Kadir, H.A.
50. Ha, K.H.
51. Lee, J.
52. Chodick, G.
53. Melzer-Cohen, C.
54. Whitlock, R.
55. Cea-Soriano, L.
56. Cantero, O.F.
57. Menzin, J.A.
58. Guthrie, M.
59. Ilomaki, J.
60. Magliano, D.
61. Show all authors +